If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
HEMATOLOGY
Reprints • emjreviews.com
EHA ANNUAL CONGRESS 2015
MESSE CONFERENCE CENTRE VIENNA, AUSTRIA
11TH-14TH JUNE 2015
Why Biosimilars Matter: An Innovative
Solution to Improve Patient Access
WHY BIOSIMILARS MATTER: AN INNOVATIVE
SOLUTION TO IMPROVE PATIENT ACCESS
Summary of presentations from the Sandoz-supported
satellite symposium held at the 20th Congress of the European
Hematology Association (EHA), Vienna,
Austria, on 13th June 2015
Chairperson
Felix Keil1
Speakers
Mark McCamish,2 Robin Foà,3 Karen Van Rassel4
1. Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, Austria
2. Sandoz, Holzkirchen, Germany
3. Hematology, ‘Sapienza’ University, Rome, Italy
4. Lymphoma Coali
HEMATOLOGY Reprints • emjreviews.com EHA ANNUAL C
WHY BIOSIMILARS MATTER: AN INNOVATIVE SOLUTION
The first biosimilar was approved in Europe
Structure (glycol structure)/ function (ADCC) rel
the same as the reference product and whos
Approvals for new therapies and combinations
regulatory approval in 40 of the Lymphoma C
Med. 2015;372(25):2380-2. 11. ZI AVD. 2015. Avail